Literature DB >> 12883536

Adenovirus-mediated interleukin-2 gene therapy of nociception.

M Z Yao1, J F Gu, J H Wang, L Y Sun, H Liu, X Y Liu.   

Abstract

The effect of adenovirus-mediated interleukin-2 (IL-2) gene on rat basal nociceptive response and chronic neuropathic pain was explored. The paw withdrawal latency induced by radiant heat was used to evaluate the antinociceptive effect of adenovirus type 5 (Ad5) and Ad5-IL-2. The results showed that intrathecal delivery of Ad5-IL-2 exhibited obvious antinociceptive effects on basal nociceptive response and chronic neuropathic pain, which were maintained for 3 and 4 weeks, respectively. This suggested that the antinociceptive effect of Ad5-IL-2 on chronic neuropathic pain was greater than its effect on basal nociceptive response. Human IL-2 mRNA was detected by in situ hybridization in the spinal pia mater and parenchyma of the lumbar, sacral, thoracic and cervical regions, and gray matter had higher level of IL-2 expression than white matter. These data demonstrated that the IL-2 gene was transfected into spinal cord regions relevant to pain modulation. The expressed IL-2 protein profile in spinal cord detected by enzyme-linked immunosorbent assay coincided almost exactly with its antinociceptive effect. This supported the hypothesis that the therapeutic effect of IL-2 gene was related to IL-2 protein expression. The study indicates that intrathecal delivery of adenovirus-mediated IL-2 gene has a relatively long antinociceptive effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883536     DOI: 10.1038/sj.gt.3301992

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

Review 1.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Authors:  Carlos Barcia; Christian Gerdes; Wei-Dong Xiong; Clare E Thomas; Chunyan Liu; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Neuron Glia Biol       Date:  2006-11

Review 3.  Viral vector-based gene transfer for treatment of chronic pain.

Authors:  Shuanglin Hao; Marina Mata; David J Fink
Journal:  Int Anesthesiol Clin       Date:  2007

Review 4.  Glia in pathological pain: a role for fractalkine.

Authors:  E D Milligan; E M Sloane; L R Watkins
Journal:  J Neuroimmunol       Date:  2008-06-10       Impact factor: 3.478

5.  Downregulation of PI3Kcb utilizing adenovirus-mediated transfer of siRNA attenuates bone cancer pain.

Authors:  Huan-Jun Huang; Mei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Efficacy of 3 Buprenorphine Formulations for the Attenuation of Hypersensitivity after Plantar Incision in Immunodeficient NSG Mice.

Authors:  Justin D Arthur; Eden D Alamaw; Katechan Jampachairsri; Patrick Sharp; Claude Nagamine; Monika K Huss; Cholawat Pacharinsak
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-09-06       Impact factor: 1.706

Review 7.  Spinal interleukin-10 therapy to treat peripheral neuropathic pain.

Authors:  Erin D Milligan; Kathryn R Penzkover; Ryan G Soderquist; Melissa J Mahoney
Journal:  Neuromodulation       Date:  2012-06-01

8.  Gene therapy: a potential approach for cancer pain.

Authors:  Chalonda R Handy; Christina Krudy; Nicholas Boulis
Journal:  Pain Res Treat       Date:  2011-06-09

9.  Development of viral vectors for gene therapy for chronic pain.

Authors:  Yu Huang; Xin Liu; Lanlan Dong; Zhongchun Liu; Xiaohua He; Wanhong Liu
Journal:  Pain Res Treat       Date:  2011-04-07

10.  HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Mol Pain       Date:  2006-02-17       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.